DJ Khaled has lost approximately 90 pounds after beginning a weight-loss journey that included the GLP-1 medication Wegovy, according to reports from People.
The 50-year-old music producer revealed his transformation in a series of interviews, noting that he has shed about 25 percent of his body weight. He currently maintains a weight between 200 and 212 pounds, having previously weighed between 295 and 300 pounds, People reported.
The musician said that his decision to prioritize his health was sparked by a difficult moment during a performance in October 2025. While attempting to get on his knees to express gratitude during his show, he found he struggled to get back up, People reported.
“Yo, you were breathing hard,” one friend told him following the incident, while another person expressed similar concerns shortly after, People reported.
“I said, alright, hold up … I gotta step my game up. I gotta get my mind right. We can’t have this,” Khaled said, according to People.
Khaled has entered into a partnership with Novo Nordisk, the pharmaceutical company that manufactures Wegovy, to share his experience with the medication, Chain Drug Review reported. The collaboration, announced on November 12, 2026, centers on a routine the musician calls “walk, golf, and Wegovy,” People reported.
To maintain his weight loss, Khaled plays 18 holes of golf up to six times a week and walks the entire course rather than using a golf cart, People reported. He also aims for at least 10,000 steps a day through walking or using a treadmill, Us Weekly reported.
“The motivation was there, the inspiration was there, working out and trying to eat better, but I needed help,” Khaled told People.
The musician also said that his family, specifically his wife, Nicole Tuck, and their two sons, Asahd, 10, and Aalam, 6, served as a primary motivation for his health journey, People reported.
Khaled has also observed changes in his wardrobe, noting that he previously wore sizes 3X or 4X and required tailoring, but can now buy clothes off the rack in sizes 1X or 2X, according to People.
“I love to put smiles on people’s faces. I love putting good energy out there. I love representing, staying in the light,” Khaled said, regarding his decision to advocate for the use of GLP-1s, according to People.
Wegovy is a prescription GLP-1 receptor agonist approved for chronic weight management when used alongside a reduced-calorie diet and increased physical activity, Chain Drug Review reported. In a 68-week clinical trial involving 1,961 adults with obesity or overweight and a related medical condition, participants using a 2.4 mg dose of Wegovy lost an average of 15 percent of their body weight, compared to 2.5 percent for those on a placebo, Chain Drug Review reported.
The medication carries a boxed warning regarding the risk of thyroid C-cell tumors, Chain Drug Review reported. The FDA has noted a potential increased risk of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION) in people taking GLP-1 drugs, NBC News reported. Novo Nordisk must also manage safety perceptions following these FDA warnings regarding thyroid and vision issues, Source 1 reported.
“Of course, I was happy – my doctor always told me I was a Rolls-Royce with junk in the trunk. And now, he’s saying, 'You need to be studied, that’s how healthy you are,'” Khaled said, according to People.
>